Lyndra Therapeutics

United States - Watertown, Massachusetts

• 24/06/2021
• Series C
• $60,500,000

Welcome to Lyndra Therapeutics: Medicine, reinvented

Imagine taking a week’s worth of medicine in a single dose, once a week. Four pills a month. Eventually, one pill a month. Lyndra Therapeutics’ LYNX™ drug delivery platform is making that possible.

Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders, with lead product candidate oral weekly risperidone (LYN-005) for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform to tackle major public health and global health challenges, with therapies including oral weekly levomethadone and oral weekly buprenorphine for opioid use disorder, a monthly oral contraception pill and oral biweekly ivermectin for malaria eradication.

Since its founding, partners have included the Bill & Melinda Gates Foundation, the NIH, AbbVie and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA and has a state-of-the-art GMP manufacturing facility in Lexington, MA.

Core purpose: reinvent medicine for a healthier world

Core values: value every voice; resilient to the core; I contribute, we deliver

Does Lyndra sound like a great fit for you? Join the Team: https://lyndra.com/about/join-the-team/

Related People

Colin GardnerCo Founder

United States - Concord, Massachusetts

Experienced President with a demonstrated history of working in the pharmaceuticals industry. Skilled in Biotechnology, Research and Development (R&D), Life Sciences, Technology Transfer, and Drug Development. Strong business development professional with a BSc, PhD focused in Chemistry from The University of Glasgow.

LinkedIn Colin Gardner